KF
ACAD icon

Kelsey Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Kelsey Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Hold
10,000
– – 0.19% 52
2026
Q1 		$223K Hold
10,000
– – 0.19% 55
2025
Q4 		$267K Buy
+10,000
New +$239K 0.23% 49

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kelsey Financial's ACAD Position: Q2 2026 in Review

Kelsey Financial held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 10,000 shares worth $253K. The position accounts for 0.19% of the portfolio, ranked #52.

Kelsey Financial first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $267K in Q4 2025. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Kelsey Financial held 10,000 shares of Acadia Pharmaceuticals worth $253K as of Q2 2026.
  • Kelsey Financial left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.19% of Kelsey Financial's portfolio in Q2 2026, its #52 holding.
  • Kelsey Financial first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Kelsey Financial's Acadia Pharmaceuticals position peaked at $267K in Q4 2025.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Kelsey Financial's 13F filing for Q2 2026, filed 10 Aug 2026.